Orphazyme no longer expects EMA decision this year

Orphazyme will likely have to wait until sometime during the first quarter of 2022 to receive a decision from the European Medicines Agency on its key candidate arimoclomol as a treatment for Niemann-Pick disease type C, the company reports.
Photo: Orphazyme/PR
Photo: Orphazyme/PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

Biotech company Orphazyme, which is based in Copenhagen, Denmark, must arm itself with more patience.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading